LETTER TO EDITOR

Disproportional enrichment of FoxP3+CD4+ regulatory T cells shapes a suppressive tumour microenvironment in head and neck squamous cell carcinoma

Dear Editor,

The efficacy of PD-1 inhibitors has fallen short in human papilloma virus (HPV)-positive head and neck squamous cell carcinoma (HNSCC), underscoring the clinical relevance of exploring the mechanism shaping treatment resistance. In this study, the suppressive tumour microenvironment of HNSCC was investigated to gain insights into anti-PD-1 resistance and conceive the better treatment option.

Based on transcriptomic data derived from the Cancer Genome Atlas (TCGA),1 HNSCC had the highest frequency of the IFN-γ-dominant subtype, with over 70% of cases classified as IFN-γ-dominant (Figure 1A). Since immune checkpoint blockade has shown modest efficacy in treating HNSCC,2–5 we investigated the key mechanisms involved in shaping an immune-suppressive tumour microenvironment that counterbalances the active IFN-γ signature. We reasoned that the robust adaptive antitumour immune response is actively suppressed by a subpopulation of tumour-infiltrating (TI) lymphocytes, and therefore investigated the expression of FoxP3, a specific marker for regulatory T cells (Tregs).6 Intriguingly, FoxP3 expression was highest in the HNSCC cohort, along with the frequency of the IFN-γ-dominant subtype (Figures 1B and S1A), although the expression of CD4, CD8A and CD8B was intermediate in HNSCC (Figure S1B–D). Therefore, we focused on TI Tregs in HNSCC, which are hypothesised to underlie the key mechanisms involved in shaping an immunosuppressive microenvironment that results in checkpoint blockade resistance.

Transcriptomic analysis of HNSCC cohort from TCGA revealed that the expressions of FoxP3 and immune checkpoints were higher in tumour tissue than in normal adjacent tissue (Figure 1C). Flow cytometry analysis of clinical samples of HNSCC patients confirmed that the frequency of Tregs was higher in tumour than in normal adjacent tissue or peripheral blood (Figures 1D and S2). Intriguingly, PD-1+ cells were more frequently observed among Tregs in tumour tissue (Figure 1E). These PD-1+ TI Tregs expressed immune checkpoint receptors and Ki-67 more frequently than PD-1− TI Tregs (Figure 1F), suggesting that these Tregs impeded CD8+ T-cell functionality (Figure S3).

Based on the previous findings of the prognostic implications of HPV status in HNSCC,7 we further classified patients in terms of HPV status and differential T-cell infiltration. Consistent with the transcriptomic data (Figure S4), immunohistochemical analysis revealed that both CD8+ T cells and Tregs exhibited greater infiltration in HPV-positive than in HPV-negative HNSCC (Figures 2A and S5), with an apparent positive correlation between the infiltration rates of CD8+ T cells and Tregs (Figure 2B). HPV-positive and CD8high HNSCC patients demonstrated more favorable outcomes than HPV-negative and CD8low patients in terms of both DFS and OS in the overall population, whereas DFS and OS did not differ according to the abundance of TI FoxP3+ T cells (Figures 2C and S6A). Next, we conducted subgroup analyses according to HPV positivity. We observed no association between CD8+ T-cell infiltration and outcome in the HPV-negative group. Interestingly, FoxP3high patients exhibited better survival outcomes in terms of DFS and OS than FoxP3low patients in the HPV-negative group; likewise, FoxP3/CD8 high patients had better prognoses than FoxP3/CD8low patients in the HPV-negative group (Figures 2D and S6B). In the HPV-positive group, CD8high patients displayed better survival outcomes than CD8low patients in terms of both DFS and OS, whereas differences between outcomes based on the abundance of TI Tregs were not evident. The FoxP3/CD8high group showed poor clinical outcomes, which was contrary to observations in HPV-negative patients (Figures 2E and S6C). Collectively, these results indicated that the balance between TI CD8+ T cells and Tregs differentially impacted individual survival according to HPV status.
To evaluate the differences in the properties between TI Tregs in HPV-positive and HPV-negative HNSCC, we first analysed Cibersort for TCGA HNSCC cohort, which revealed that the relative fraction of Tregs was larger in HPV-positive than in HPV-negative HNSCC (Figure 2F). Moreover, gene set enrichment analysis revealed that the expression of genes downstream of FoxP3 was significantly upregulated in HPV-positive compared to that in HPV-negative HNSCC (Figure 2G). To address whether Tregs shape the suppressive tumour microenvironment in a quantitative or qualitative manner, we assessed the frequency and characteristics of TI Tregs using per-cell-based analysis. Indeed, FoxP3+ Tregs were significantly enriched in HPV-positive than in HPV-negative HNSCC (Figure 2H), albeit the expression of immune checkpoint inhibitory receptors in TI Tregs did not differ significantly between two groups (Figure 2I). In contrast, the expression of Ki-67 was slightly higher in TI Tregs from HPV-positive than HPV-negative tumours (Figure 2I). This trend was maintained when we analysed the frequency of immune checkpoint receptors co-expressing in PD-1+ cells among TI Tregs (Figure S7).

Next, we investigated TCGA HNSCC data to identify the expression of upstream regulators during Treg differentiation. The expression of TGFBI was higher in HPV-negative HNSCC, whereas that of TGFBR2, TGFBR3 and IL10 did not differ based on HPV status (Figure 3A). In contrast, the expression of IDOI and IDO2 was highly upregulated in HPV-positive compared to that in HPV-negative HNSCC (Figure 3A). Furthermore, the correlation between the expression of IDOI or IDO2 and the relative frequency of Tregs among CD4+ T cells was stronger in HPV-positive than in HPV-negative HNSCC (Figure 3B), suggesting that IDO pathway activation can be one of the key mechanisms involved in Treg induction and maintenance of the HPV-positive HNSCC tumour microenvironment. We further confirmed via single-cell transcriptomic data analysis that IDO was highly expressed in dendritic cells from the tumour microenvironment (Figure S8A), as well as in CD14+HLA-DR+CD11c+ mature dendritic cells from PBMCs upon stimulation (Figure S8B and C).

Supporting the aforementioned findings, promising clinical activity was observed in a patient with HPV-positive HNSCC in an ongoing study of combined treatment with the IDO inhibitor epacadostat and the PD-1 inhibitor pembrolizumab (Figure 3C and D).

In conclusion, we identified that Tregs hamper active antitumour immunity in HNSCC, underlying anti-PD-1 resistance. In particular, activation of the IDO pathway contributes to the enrichment of Tregs in HPV-positive HNSCC. A combined PD-1 and IDO blockade elicited a consequential response in HPV-positive HNSCC. Exploiting strategies to target Tregs or the IDO pathway would benefit patients with HPV-positive HNSCC.

ACKNOWLEDGEMENTS
The authors would like to thank the patients and their families who participated in this study. This study was supported by the National Research Foundation (NRF) grants funded by the Korea government (NRF-2019M3A9B6065231, NRF-2021R1A2C2094629 and 2017M3A9E9072669 to HRK; 2017RI1A5A1014560 and 2019M3A9B6065221 to SJH; NRF-2021R1I1A1A01059271 to CGK). This study was also supported by a Severance Hospital Research fund for Clinical excellence (C-2021-0016) and YUHAN research grant to HRK, the Korean Health Technology R&D Project (HV20C0144 to SJH) through the Korean Health Industry Development Insti-

---

**FIGURE 1** Disproportional enrichment of suppressive FoxP3+CD4+ regulatory T cells in the tumour microenvironment of HNSCC. (A) The proportions of IFN-γ dominant subtypes were analysed from TCGA pan-cancer transcriptome data. The IFN-γ-dominant subtype was characterised by a strong CD8 signal, the greatest diversity of T-cell receptors (TCRs), and the highest density of tumour-infiltrating lymphocytes (TILs). This subtype also exhibited the highest expression levels of chemokines such as CXCL10 and CCL5. All of these traits confer a strong antitumour immune response, a prerequisite for immune checkpoint blockade response. Abbreviations for the cancer types were followed on the suggestions of the National Cancer Institute Genomic Data Commons (http://gdc.cancer.gov.). (B) Correlation between the frequency of IFN-γ dominant subtypes and the expression of FoxP3 mRNA from TCGA pan-cancer cohort. RPKM, reads per kilobase per million. (C) Expression of FoxP3, PDCD1, HAVCR2, LAG3, TIGIT and CTLA4 mRNA levels in normal tissue and tumour tissue were analysed from TCGA HNSCC cohort. (D)–(E) Flow cytometric analysis of TI CD4+ T cells or FoxP3+CD4+ regulatory T cells isolated from HNSCC patients who underwent surgical resection. Gating strategies for analysing the flow cytometry data are shown in Figure S2. (D) Representative flow cytometry plots display the expression of FoxP3 in CD4+ T cells from peripheral blood mononuclear cells (PBMCs), adjacent normal tissue and tumour tissue of HNSCC patients (left). The expression level of FoxP3+ cells gated on CD4+ T cells by tissue dependent sites (right). (E) Representative flow cytometry plots show the PD-1+ populations of FoxP3+CD4+ Tregs from PBMCs, adjacent normal tissue, and tumour tissue of HNSCC patients (left). The frequency of PD-1+ cells in FoxP3+CD4+ regulatory T cells from the aforementioned tissue sites of HNSCC patients (right). (F) Flow cytometric analysis of the expression of CTLA-4, TIM-3, TIGIT, ICOS and Ki67 in TI FoxP3+CD4+ Tregs into those with PD-1-negative and positive populations. Percentage of expressing each molecule in the two subpopulations of TI Tregs. Each line in the graph indicates the same tumour tissue derived from each individual patient. SSC, side-scattered light. ***p < .001; ****p < .0001. All statistical analyses were performed using paired and unpaired Student’s t test.
tute (KHIDI) funded by the Ministry of Health & Welfare and Young Medical Scientist Research Grant Program of the Daewoong Foundation (DY20206P to CGK).

CONFLICT OF INTEREST
The authors declare no potential conflicts of interest.

Seyeon Park1
Chang Gon Kim2
Dahee Kim3
Min Hee Hong2
Eun Chang Choi3
Se-Heon Kim3
Young Min Park3
Jinna Kim4
Sun Ock Yoon5
Gamin Kim2
Sunhye Shin2
Kyungsoo Kim1
Yoon Woo Koh3
Sang-Jun Ha1
Hye Ryun Kim1

1Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea
2Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
3Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea
4Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea
5Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea

Correspondence
Hye Ryun Kim, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50–1 Yonsei-ri, Seodaemun-gu, Seoul 03722, Republic of Korea.
Email: nobelg@yuhs.ac

Sang-Jun Ha, Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 50–1 Yonsei-ri, Seodaemun-gu, Seoul 03722, Republic of Korea.
Email: sjha@yonsei.ac.kr

Yoon Woo Koh, Department of Otorhinolaryngology, Severance Hospital, Yonsei University College of Medicine, 50–1 Yonsei-ri, Seodaemun-gu, Seoul 03722, Republic of Korea.
Email: ywkohent@yuhs.ac

Seyeon Park, Chang Gon Kim and Dahee Kim contributed equally.

ORCID
Dahee Kim https://orcid.org/0000-0001-7286-1334
Min Hee Hong https://orcid.org/0000-0003-3490-2195
Hye Ryun Kim https://orcid.org/0000-0002-1842-9070

REFERENCES
1. Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812-830.e814.
2. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-1928.
3. Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156-167.

FIGURE 2 Disease-free survival outcome and immune phenotypic characteristics according to HPV positivity. (A) Infiltration of CD8+ cells and FoxP3+ cells in HPV-negative (N = 223) and HPV-positive (N = 149) HNSCC and (B) the correlation between infiltration of CD8+ cells and FoxP3+ cells were measured by immunohistochemistry (IHC). Representative IHC images of CD8, FoxP3 and p16 in HNSCC tumour tissue were shown in Figure S5. (C) Disease-free survival analysis according to HPV positivity, CD8+ cell infiltration and FoxP3+ cell infiltration in the overall patients. (D) Disease-free survival analysis according to CD8+ cell infiltration, FoxP3+ cell infiltration and the ratio of FoxP3+ versus CD8+ cells in patients with HPV-negative HNSCC. (E) Disease-free survival analysis according to CD8+ cell infiltration, FoxP3+ cell infiltration and the ratio of FoxP3+ cell versus CD8+ cell in patients with HPV-positive HNSCC. (F) Relative fraction of Tregs among total immune cells were analysed from TCGA HNSCC cohort by deconvolution method. (G) Gene set enrichment analysis (GSEA) of FoxP3 target gene sets in tumour tissues was performed using the transcriptionome from patients with HPV-positive HNSCC versus those with HPV-negative HNSCC. (H)–(I) The expression level of FoxP3 and immune checkpoint molecules was measured by flow cytometry in HPV-positivity manners. (H) Representative flow cytometry plots were presented the fraction of FoxP3+ cells in T1 CD4+ T cells following HPV positivity (left). Percentage of FoxP3-expressing cells in the T1 CD4+ T-cell population according to HPV positivity (right). (I) The proportion of CTLA-4+, PD-1+, TIM-3+, TIGIT+, ICOS+ and Ki-67+ cells in the T1 FoxP3+ CD4+ regulatory T-cell population according to HPV status. DFS, disease-free survival. ns, not significant; *p < .05; **p < .01; ****p < .0001. Statistical analyses were performed (A) using unpaired Student’s t test, (B) using Logistic regression, (C) through (E) using Long-rank test and in (F) through (I) using unpaired Student’s t test.
FIGURE 3  IDO pathway is involved in the enrichment of Tregs in HPV-positive HNSCC and antitumour efficacy of combined anti-PD-1 and IDO inhibitor. (A) Expression of upstream regulators for Treg induction in HNSCC. Expression of TGFBI, TGFBI2, TGFBI3, IL10, IDO1 and IDO2 mRNA levels derived from TCGA HNSCC cohort according to HPV status. (B) Correlation between relative frequency of Treg among CD4<sup>+</sup> T cells and the expression of IDO1 and IDO2 mRNA in the HPV-positive and HPV-negative patients from TCGA HNSCC cohort, respectively. (C), (D) Case study of antitumour efficacy of combined with pembrolizumab and epacadostat. A patient with oropharyngeal cancer with lung metastasis was enrolled in prospective trials (NCT03358472) and achieved partial response with more than 70% tumour reduction. This patient was progression-free for 134 weeks, even after the scheduled discontinuation of epacadostat and pembrolizumab after completion of 35 cycles. (C) Representative CT scan images and (D) the summation of target lesion showing the reduction of tumour lesion. During the overall treatment course, the toxicity profiles of the combined IDO and PD-1 inhibitors were manageable, without any dose interruption or discontinuation required. ****p < .0001. Statistical analyses were performed (A) using unpaired Student's t test and (B) using Pearson's correlation test.
4. Baum J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, Phase II study. *J Clin Oncol.* 2017;35(14):1542-1549.

5. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. *N Engl J Med.* 2016;375(19):1856-1867.

6. Wing JB, Tanaka A, Sakaguchi S. Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer. *Immunity.* 2019;50(2):302-316.

7. Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. *Nat Rev Cancer.* 2018;18(5):269-282.

8. Puram SV, Tirosh I, Parikh AS, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. *Cell.* 2017;171(7):1611-1624.e1624.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.